文献速递心力衰竭与心肌病

急性失代偿性心力衰竭早期启用恩格列净对利尿与肾功能的影响(EMPAG-HF)

Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF).
PubMed 文献 · Circulation · 2022-06-29

主要终点 5 天累积尿量在恩格列净组增加 25%(中位 10.8 对 8.7 L,组间差估计 2.2 L,95%CI 8.4 至 3.6;P=0.003),利尿效率提高,肾功能与肾损伤标志物无显著影响,NT-proBNP 下降更明显,安全事件无差异。

要点

  • 急性失代偿性心衰早期加用恩格列净 25 mg/日可增加 5 天累积尿量。
  • 恩格列净提高利尿效率,未影响 eGFR 及尿蛋白等肾损伤标志物。
  • 恩格列净组 NT-proBNP 下降更明显,安全事件与安慰剂无差异。

核心结论

  • 急性失代偿性心衰早期在标准利尿治疗基础上加用恩格列净可增加尿量且不影响肾功能。

研究设计与样本

  • 干预为恩格列净 25 mg 每日或安慰剂,叠加包括袢利尿剂在内的标准减充血治疗。

主要发现

  • 5 天累积尿量中位 10.8 对 8.7 L,组间差估计 2.2 L(95%CI 8.4 至 3.6),P=0.003。
  • 利尿效率组间差 14.1 mL 尿/毫克呋塞米当量(95%CI 0.6-27.7),P=0.041。
  • eGFR 51±19 对 54±17 mL/min per 1.73 m²,P=0.599;尿总蛋白 492±845 对 503±847 mg/g 肌酐,P=0.975;尿 α1-微球蛋白 55.4±38.6 对 31.3±33.6 mg/g 肌酐,P=0.066。
  • 5 天后 NT-proBNP 变化 -1861 对 -727.2 pg/mL,斜率商 0.89(95%CI 0.83-0.95),P<0.001。
  • 两组安全事件发生率无差异。

临床怎么用

  • 对急性失代偿性心衰住院患者,可考虑在住院 12 小时内早期加用恩格列净 25 mg/日以增强利尿。
  • 早期加用恩格列净时需监测尿量与肾功能,但本研究未显示肾功能或肾损伤标志物恶化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Effective diuretic regimens using loop diuretics in patients with acute decompensated heart failure are often limited by the development of worsening kidney function. Sodium-glucose cotransporter-2 inhibitors induce glucosuria and sodium excretion with nephroprotective effects in patients with stable heart failure but their role in acute decompensated heart failure is unclear. METHODS: In this single-center, prospective, double-blind, placebo-controlled, randomized study, we randomly assigned patients with acute decompensated heart failure to empagliflozin 25 mg daily or placebo in addition to standard decongestive treatments that included loop diuretics. The primary end point was cumulative urine output over 5 days. Secondary end points included diuretic efficiency, dynamics in markers of kidney function and injury, and NT-proBNP (N-terminal pro-B-type natriuretic peptide). RESULTS: Sixty patients were randomized within 12 hours of hospitalization for acute decompensated heart failure. Addition of empagliflozin daily to standard medical treatment of acute decompensated heart failure resulted in a 25% increase in cumulative urine output over 5 days (median 10.8 versus 8.7 L mL in placebo, group difference estimation 2.2 L [95% CI, 8.4 to 3.6]; P=0.003). Empagliflozin increased diuretic efficiency compared with placebo (14.1 mL urine per milligram furosemide equivalent [95% CI, 0.6-27.7]; P=0.041) without affecting markers of renal function (estimated glomerular filtration rate, 51±19 versus 54±17 mL/min per 1.73 m²; P=0.599) or injury (total urinary protein, 492±845 versus 503±847 mg/g creatinine; P=0.975; and urinary α1-microglobulin, 55.4±38.6 versus 31.3±33.6 mg/g creatinine; P=0.066) with more pronounced decrease in NT-proBNP in the empagliflozin group compared with placebo (-1861 versus -727.2 pg/mL after 5 days; quotient in slope, 0.89 [95% CI, 0.83-0.95]; P<0.001). There were no differences in the incidence of safety events between groups. CONCLUSIONS: Early addition of empagliflozin to standard diuretic therapy increases urine output without affecting renal function in patients with acute decompensated heart failure. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT04049045.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Schulze, Bogoviku, Westphal, et al. Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF). Circulation. 2022. PMID: 35766022. doi:10.1161/CIRCULATIONAHA.122.059038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。